Amarin spent years, millions of dollars and a lot of willpower proving its fish oil-based drug Vascepa really could cut the risk of heart attacks, strokes and other cardiovascular problems. To make that effort pay off, it needs to keep that proof to itself. That's just what the drugmaker did in settling two lawsuits with fish oil supplement manufacturers who'd allegedly co-opted the results of Amarin's landmark Reduce-It trial. And in touting its double win, Amarin said it has lawyer...
READ MORE
|
US President Donald Trump has not just spooked the Indian IT companies, even the billion dollar Indian drug industry is rattled by the protectionist noises coming from White House....
READ MORE
|
Johnson and Johnson faces about 14,200 lawsuits alleging harm from talc, and Monday marks its next big test. In a New Jersey courtroom, the drugmaker plans to challenge expert evidence set to be presented at trial and the judges decision will determine the fate of most of the outstanding lawsuits. That evidence is key to 85% of the cases grouped for consideration in J&J's home state. If the court decides the plaintiffs' expert evidence can't be used in court, then "there'...
READ MORE
|
In a small, randomised Phase I/II clinical trial (SAT1), researchers at University of California San Diego School of Medicine say a 100-year-old drug called suramin, originally developed to treat African sleeping sickness, was safely administered to children with autism spectrum disorder (ASD), who subsequently displayed measurable, but transient, improvement in core symptoms of autism....
READ MORE
|
Innovation Pharmaceuticals, a clinical stage biopharmaceutical company, announces today that the Company and Fox Chase Chemical Diversity Center, Inc. have amended an earlier collaborative research agreement related to antifungal drug discovery work.
Under the amended terms, and in exchange for a six (6) percent fee tied to all potential future proceeds—including upfront payments, milestone payments and royalties—the Company is granting FCCDC all discovery, intellectua...
GLOBENEWSWIRE
READ MORE
|
Scientists in Israel have developed a breath test that can detect people with early-stage Parkinson's disease. Neurons in Parkinson's disease The team from Technion Israel Institute of Technology had previously shown that the test can detect people with Parkinson's disease who are already receiving treatment. Now, in a paper published in the journal ACS Chemical Neuroscience, they report how the test which analyzes molecules in exhaled breath detected people with early-stage Parkinso...
READ MORE
|